Stock Screener App

무료 -

설치하다

30.18

3.61% 1.065

Mineralys Therapeutics Inc (MLYS)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측

Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스

Did Index Removal, ENDO 2026 Data and a $150M Raise Just Shift Mineralys Therapeutics' (MLYS) Investment Narrative? - simplywall.st

A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger - Yahoo Finance

Have Insiders Sold Mineralys Therapeutics Shares Recently? - simplywall.st

Have Mineralys Therapeutics Insiders Been Selling Stock? - Moomoo

Is Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat’s Expanding Cardiovascular Potential? - Insider Monkey

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) - 富途牛牛

Mineralys Therapeutics Insider Sold Shares Worth $2,696,322, According to a Recent SEC Filing - marketscreener.com

Mineralys Therapeutics Insider Sold Shares Worth $1,960,601, According to a Recent SEC Filing - marketscreener.com

5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey

Insider Sell: CEO Jon Congleton Sells 75,000 Shares of Mineralys Therapeutics Inc (MLYS) - GuruFocus

Form 4 Mineralys Therapeutics Inc For: 30 June By Investing.com - Investing.com Australia

Mineralys Therapeutics CEO Jon Congleton sells $1.96m in stock - Investing.com

Mineralys Therapeutics CCO Eric Warren sells $2.7m in shares By Investing.com - Investing.com Australia

Mineralys Therapeutics CCO Eric Warren sells $2.7m in shares - Investing.com UK

Mineralys Therapeutics CEO Jon Congleton sells $1.96m in stock By Investing.com - Investing.com Nigeria

Mineralys Therapeutics (MLYS) CEO sells 75K shares under Rule 10b5-1 plan - Stock Titan

Mineralys (NASDAQ: MLYS) CCO sells shares after option exercise - Stock Titan

Mineralys Therapeutics (MLYS) Form 144 lists 90,730 shares sold and RSU vesting - Stock Titan

Form 144 Mineralys Therapeutics For: 29 June By Investing.com - Investing.com Nigeria

Mineralys Therapeutics (NASDAQ: MLYS) flagged sale of 104,124 shares via cashless exercise - Stock Titan

Mineralys Therapeutics, Inc.(NasdaqGS:MLYS) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com

Mineralys Therapeutics, Inc.(NasdaqGS:MLYS) dropped from Russell 3000E Growth Benchmark - marketscreener.com

Mineralys Therapeutics, Inc.(NasdaqGS: MLYS) dropped from Russell Microcap Index - marketscreener.com

Mineralys Therapeutics, Inc.(NasdaqGS: MLYS) dropped from Russell 3000E Index - marketscreener.com

Enterprise value to EBITDA forward of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView

Price to earnings forward of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView

Understanding the Setup: (MLYS) and Scalable Risk - Stock Traders Daily

Price to sales forward of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView

Price to book forward of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView

What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision - AOL.com

MLYS Forecast — Price Target — Prediction for 2027 - TradingView

Mineralys Therapeutics, Inc. Actuals & Estimates (NASDAQ:MLYS) - TradingView

Mineralys Therapeutics, Inc. Actuals & Estimates (BOATS:MLYS) - TradingView

Mineralys Therapeutics Inc (MLYS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Mineralys Therapeutics (MLYS) Edges Higher as Shares Hold Above Key SupportSign of Strength - Město Břeclav

Mineralys Therapeutics Inc (MLYS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Mineralys Therapeutics Inc (MLYS) Institutional Confidence - TradingKey

Mineralys: Limited Differentiation Makes Lorundrostat A Weak Competitor - Seeking Alpha

Mineralys Therapeutics Inc (MLYS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Mineralys Therapeutics Inc (MLYS) Valuation: PE, PB & Fair Value Analysis - TradingKey

Mineralys Therapeutics director Karydas sells $75,000 in stock By Investing.com - Investing.com India

Mineralys Therapeutics CMO Rodman sells $350,086 in stock By Investing.com - Investing.com India

Mineralys Therapeutics (MLYS) CMO sells 14,474 shares, exercises options - Stock Titan

Director at Mineralys Therapeutics (MLYS) trades 3,000 shares under 10b5-1 plan - Stock Titan

Mineralys Therapeutics director Karydas sells $75,000 in stock - Investing.com

Mineralys Therapeutics CMO Rodman sells $350,086 in stock - Investing.com

Mineralys Therapeutics Inc (MLYS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Mineralys Therapeutics Inc (MLYS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Mineralys Therapeutics Inc (MLYS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Mineralys Therapeutics Inc (MLYS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Mineralys Therapeutics (NASDAQ: MLYS) files Form 144 to sell 4,584 shares - Stock Titan

Mineralys Therapeutics (MLYS) Rule 144: 3,000-share cashless exercise - Stock Titan

Mineralys Therapeutics (MLYS) Prices $150M Public Offering of Common Stock - Insider Monkey

The Technical Signals Behind (MLYS) That Institutions Follow - Stock Traders Daily

Mineralys Therapeutics (MLYS) affiliate lists multi-date sales and a 3,542-share exercise - Stock Titan

Mineralys Therapeutics Reports Significant Reductions in Heart Failure Risk Biomarkers Associated with Lorundrostat in Proteomic Analysis - Quiver Quantitative

INSM

$113.49

1.16%

ROIV

$35.27

0.23%

RPRX

$57.95

1.95%

ONC

$308.33

0.48%

MRNA

$82.23

0.32%

RVMD

$190.47

0.31%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기 | MarketWatch에서 열기 | EDGAR에서 열기 | 로이터에서 공개